Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Rating of “Hold” by Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have earned a consensus recommendation of “Hold” from the twenty ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $9.65.

Several research firms recently commented on SAGE. Oppenheimer reduced their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price on the stock in a research report on Thursday, November 21st. HC Wainwright reissued a “neutral” rating and set a $12.00 target price (down previously from $14.00) on shares of Sage Therapeutics in a research report on Wednesday. TD Cowen cut their target price on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, November 21st. Finally, Truist Financial cut their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, October 30th.

Sage Therapeutics Trading Down 0.4 %

Shares of SAGE opened at $7.16 on Thursday. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $27.39. The company has a market cap of $437.98 million, a P/E ratio of -1.28 and a beta of 0.94. The company’s fifty day simple moving average is $6.34 and its 200-day simple moving average is $6.93.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. Analysts predict that Sage Therapeutics will post -6.46 earnings per share for the current fiscal year.

Institutional Trading of Sage Therapeutics

Hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN raised its holdings in Sage Therapeutics by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 33,051 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 7,087 shares in the last quarter. ExodusPoint Capital Management LP acquired a new stake in Sage Therapeutics during the fourth quarter worth approximately $759,000. Geode Capital Management LLC raised its holdings in Sage Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,256,903 shares of the biopharmaceutical company’s stock worth $6,827,000 after purchasing an additional 14,049 shares in the last quarter. Fox Run Management L.L.C. grew its position in shares of Sage Therapeutics by 199.0% during the fourth quarter. Fox Run Management L.L.C. now owns 48,950 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 32,579 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Sage Therapeutics during the fourth quarter worth approximately $49,000. Institutional investors and hedge funds own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.